表格類別： 股票 狀態： 新提交 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) | 2. 股份分類 | | 普通股 | 股份類別 A | | 於香港聯交所上市 | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | | | 說明 | 人民幣股份 （於深圳證券交易所主板上市，股份代號：000513) | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | | 2025年8月21日 | 604,293,313 | | | 0 | | 604,293,313 | | 1). 其他 ...

智通财经APP讯，丽珠医药(01513)发布公告，于2025年8月22日，该公司斥资299.63万元回购7.33万股A 股。 该信息由智通财经网提供 ...

相关事件 格隆汇8月22日丨丽珠医药(01513.HK)公告，8月22日耗资299.6万元回购7.33万股A股。 丽珠医药(01513.HK)8月22日耗资299.6万元回购7.33万股A股 丽珠医药(01513.HK)8月21日耗资300万元 回购7.21万股A股 ...

丽珠医药(01513)发布公告，于2025年8月22日，该公司斥资299.63万元回购7.33万股A股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 麗珠醫藥集團股份有限公司 呈交日期： 2025年8月22日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01513 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關 ...

天眼查商业履历信息显示，丽珠医药集团股份有限公司，成立于1985年，位于珠海市，是一家以从事医 药制造业为主的企业。企业注册资本94358.5025万人民币，实缴资本93555.2687万人民币。公司法定代 表人为朱保国。 通过天眼查大数据分析，丽珠医药集团股份有限公司共对外投资了47家企业，参与招投标项目491次， 知识产权方面有商标信息623条，专利信息343条，此外企业还拥有行政许可74个。 来源：金融界 金融界消息 截至2025年8月22日收盘，丽珠集团（000513）报收于41.02元，下跌0.65%，换手率 2.06%，成交量12.04万手，成交金额4.93亿元。 资金流向方面，今日主力资金净流入4447.28万元，占比成交额9.02%。其中，超大单净流入3451.93万 元、占成交额7.0%，大单净流入995.35万元、占成交额2.02%，中单净流出流出349.39万元、占成交额 0.71%，小单净流出4097.88万元、占成交额8.31%。 丽珠集团最新一期业绩显示，截至2025中报，公司营业总收入62.72亿元、同比减少0.17%，归属净利润 12.81亿元，同比增长9.40%，扣非净利润1 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company achieved a revenue of 6.272 billion yuan in H1 2025, a slight decrease of 0.17% year-on-year, while the net profit attributable to the parent company was 1.281 billion yuan, reflecting a growth of 9.40% year-on-year [4] - The company maintains a strong gross margin of 66.02% and a net profit margin of 24.73%, with significant improvements in net profit margin by 3.17 percentage points year-on-year [4] - The company is expected to continue its differentiated innovation strategy, with projected net profits of 2.276 billion yuan, 2.521 billion yuan, and 2.801 billion yuan for the years 2025, 2026, and 2027 respectively, leading to an EPS of 2.52 yuan, 2.79 yuan, and 3.10 yuan per share [4] Financial Performance Summary - In H1 2025, the company's sales expenses ratio was 27.69%, management expenses ratio was 4.77%, and R&D expenses ratio was 6.89% [4] - The company’s chemical preparations generated 3.270 billion yuan in revenue, with notable performance in digestive products (1.351 billion yuan, +3.87%) and psychiatric products (0.317 billion yuan, +6.89%) [5] - The company’s diversified product matrix is advancing rapidly, with several innovative drugs in the pipeline, including a long-acting formulation of Aripiprazole and a small nucleic acid drug targeting uric acid production [6] Financial Projections - The company is projected to have a revenue of 12.247 billion yuan in 2025, with a year-on-year growth of 3.7% [7] - The projected P/E ratios for 2025, 2026, and 2027 are 16.4, 14.8, and 13.3 respectively, indicating a favorable valuation trend [7]

Group 1 - A total of 21 companies were investigated by institutions on August 21, with 16 companies specifically targeted by funds [1] - Desay SV Automotive received the most attention, with 46 funds participating in its investigation, followed by Livzon Pharmaceutical and Ice Wheel Environment with 30 and 13 funds respectively [1] - The companies investigated are from various sectors, with the computer industry having the highest representation at 4 companies, followed by the pharmaceutical and mechanical equipment sectors with 3 and 2 companies respectively [1] Group 2 - Among the companies investigated, only one has a total market capitalization exceeding 50 billion yuan, while six companies have a market capitalization below 10 billion yuan [1] - In terms of market performance, 13 out of the investigated stocks increased in value over the past five days, with Tianrongxin, Langxin Group, and Desay SV Automotive showing the highest gains of 16.10%, 9.16%, and 8.71% respectively [1] - Conversely, three stocks experienced declines, with Fuyuan Pharmaceutical, Xing Shuai Er, and Hebai Group showing the largest drops of 16.62%, 2.58%, and 1.61% respectively [1] Group 3 - In the past five days, five stocks saw net inflows of funds, with Desay SV Automotive attracting the most at 220 million yuan, followed by Langxin Group and Tianrongxin with 181 million yuan and 160 million yuan respectively [2] - Among the companies investigated, 15 have released their semi-annual reports, with Tianrongxin and Desay SV Automotive reporting the highest year-on-year net profit growth rates of 68.56% and 45.82% respectively [2] - A detailed list of companies investigated includes Desay SV Automotive, Livzon Pharmaceutical, Ice Wheel Environment, and others, along with their respective fund participation and recent stock performance [2]

Group 1: Yuntianhua (云天化) - Yuntianhua's 2025 semi-annual report details phosphate fertilizer exports, phosphate rock prices, and production volumes of phosphate ammonium, among other topics [1] - Phosphate fertilizer exports are strictly adhering to domestic supply and price stability policies, with high sulfur prices impacting costs [1] - The company is progressing with the trial production of Kunyang No. 2 Mine and the exploration of Zhenxiong phosphate mine, which may be injected into the listed company in the future [1] - Phosphate ammonium production and sales have decreased due to product structure adjustments and maintenance [1] - The supply-demand balance for phosphate rock remains tight, with prices expected to stay high in the short term [1] Group 2: *ST Chengchang (铖昌) - The company has seen a significant increase in orders and projects due to recovering downstream user demand [2] - Remote sensing satellite projects are expected to enter small batch production in 2024 and mass production in 2025, indicating substantial growth potential [2] - The company maintains a stable gross profit margin by improving R&D efficiency and optimizing production processes [2] - The average project cycle is shortening as demand increases, with faster acceptance rates [2] - The company has a technological advantage in the low-orbit satellite sector, which is anticipated to be a new growth point [2] Group 3: Desay SV (德赛西威) - Desay SV achieved a revenue of 14.644 billion yuan in the first half of 2025, a year-on-year increase of 25.25%, with a net profit of 1.223 billion yuan, up 45.82% [3] - The company has established overseas branches, with factories in Indonesia and Mexico already in production, and a smart factory in Spain expected to start mass production in 2026 [3] - The smart driving business generated revenue of 4.147 billion yuan, growing 55.49% year-on-year, with the company holding the largest market share in domestic auxiliary driving domain controllers [3] - The smart cockpit business reported sales of 9.459 billion yuan, an 18.76% increase, with new project orders for the fifth-generation platform [3] Group 4: LIZHU Group (丽珠集团) - LIZHU Group anticipates single-digit revenue growth for the year, with profit growth expected to outpace revenue [4] - The P-CAB tablet has submitted a listing application, while the injection is expected to be approved in the first half of 2029 [4] - The IL-17A/F is projected to be approved in the first half of 2027, with significant commercialization potential [4] - The micro-sphere product market shows great potential, with plans for long-acting micro-sphere formulations and psychiatric products [4] - The small nucleic acid drug LZHN2408 is progressing rapidly, with enrollment for Phase Ib expected to complete in September [4]

Group 1: Zhenghai Magnetic Materials (正海磁材) - In the first half of 2025, Zhenghai Magnetic Materials achieved total revenue of 3.057 billion yuan, a year-on-year increase of 20.42%, but net profit decreased by 24.39% [1] - The company experienced improved operational efficiency in Q1, but faced profit pressure in Q2 due to changes in the international economic environment and intensified domestic market competition [1] - Product shipments increased by over 20% year-on-year, with shipments in the energy-saving and new energy vehicle markets growing by over 30% [1] Group 2: Shengyi Electronics (生益电子) - Shengyi Electronics reported a 91.00% increase in revenue and a 452.11% increase in net profit for the first half of 2025, driven by optimized product structure and a higher proportion of high-value-added products [2] - The company is focusing on the 800G high-speed switch market in telecommunications and enhancing its presence in the automotive electronics sector [2] - The Thai production base project is progressing steadily, having received investment incentives, and the smart computing center's first phase has begun trial production [2] Group 3: Desay SV (德赛西威) - Desay SV achieved revenue of 14.644 billion yuan in the first half of 2025, a year-on-year increase of 25.25%, with net profit rising by 45.82% [3] - The company has established overseas branches and commenced production in factories located in Indonesia and Mexico, with a smart factory in Spain expected to start mass production in 2026 [3] - The smart driving business generated revenue of 4.147 billion yuan, reflecting a year-on-year growth of 55.49%, while the smart cockpit business saw sales of 9.459 billion yuan, up 18.76% [3] Group 4: Livzon Pharmaceutical Group (丽珠集团) - Livzon Pharmaceutical Group anticipates single-digit revenue growth for the year, with profit growth expected to outpace revenue growth [4] - The company has submitted a listing application for P-CAB tablets and expects approval for injection products in the first half of 2029 [4] - The market potential for microsphere products is significant, with ongoing development in long-acting microsphere formulations and psychiatric products [4]